105 related articles for article (PubMed ID: 9227225)
21. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Denis F; Desbiez-Bourcier AV; Chapiron C; Arbion F; Body G; Brunereau L
Eur J Surg Oncol; 2004 Dec; 30(10):1069-76. PubMed ID: 15522553
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging.
Barentsz JO; Berger-Hartog O; Witjes JA; Hulsbergen-van der Kaa C; Oosterhof GO; VanderLaak JA; Kondacki H; Ruijs SH
Radiology; 1998 Jun; 207(3):791-7. PubMed ID: 9609906
[TBL] [Abstract][Full Text] [Related]
23. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging.
Kvistad KA; Rydland J; Vainio J; Smethurst HB; Lundgren S; Fjøsne HE; Haraldseth O
Radiology; 2000 Aug; 216(2):545-53. PubMed ID: 10924584
[TBL] [Abstract][Full Text] [Related]
24. [A pharmacokinetic analysis of Gd-DTPA enhancement in MRT in breast carcinoma].
Hess T; Knopp MV; Hoffmann U; Brix G; Junkermann H; Zuna I; von Fournier D; van Kaick G
Rofo; 1994 Jun; 160(6):518-23. PubMed ID: 8011997
[TBL] [Abstract][Full Text] [Related]
25. Dynamic magnetic resonance mammography of both breasts following local excision and radiotherapy for breast carcinoma.
Murray AD; Redpath TW; Needham G; Gilbert FJ; Brookes JA; Eremin O
Br J Radiol; 1996 Jul; 69(823):594-600. PubMed ID: 8696694
[TBL] [Abstract][Full Text] [Related]
26. [MR imaging for breast cancer].
Seki T; Hachiya J; Nitatori T; Yokoyama K; Fukushima H; Uchigasaki S
Nihon Geka Gakkai Zasshi; 1996 May; 97(5):347-56. PubMed ID: 8709936
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
28. Ductal carcinoma in situ: is there a role for MRI?
Zuiani C; Francescutti GE; Londero V; Zunnui I; Bazzocchi M
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):89-95. PubMed ID: 12585661
[TBL] [Abstract][Full Text] [Related]
29. MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease.
Rieber A; Nüssle K; Merkle E; Kreienberg R; Tomczak R; Brambs HJ
Eur Radiol; 1999; 9(6):1107-12. PubMed ID: 10415244
[TBL] [Abstract][Full Text] [Related]
30. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
31. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement.
Neubauer H; Li M; Kuehne-Heid R; Schneider A; Kaiser WA
Br J Radiol; 2003 Jan; 76(901):3-12. PubMed ID: 12595319
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
33. MR imaging of the contralateral breast in patients after breast-conserving therapy.
Viehweg P; Rotter K; Laniado M; Lampe D; Buchmann J; Kölbl H; Heywang-Köbrunner S
Eur Radiol; 2004 Mar; 14(3):402-8. PubMed ID: 14531008
[TBL] [Abstract][Full Text] [Related]
34. [Can follow-up controls improve the accuracy of MR mammography? A retrospective analysis of MR mammography follow-up studies].
Betsch A; Arndt E; Stern W; Wallwiener D; Claussen CD; Müller-Schimpfle M
Rofo; 2001 Jan; 173(1):24-30. PubMed ID: 11225413
[TBL] [Abstract][Full Text] [Related]
35. Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients.
Nagashima T; Sakakibara M; Nakamura R; Arai M; Kadowaki M; Kazama T; Nakatani Y; Koda K; Miyazaki M
Eur J Radiol; 2006 Nov; 60(2):270-4. PubMed ID: 16926079
[TBL] [Abstract][Full Text] [Related]
36. Magnetic resonance imaging of intraductal papillomas: typical findings and differential diagnosis.
Dietzel M; Kaiser C; Baltzer PA
J Comput Assist Tomogr; 2015; 39(2):176-84. PubMed ID: 25423553
[TBL] [Abstract][Full Text] [Related]
37. Variation of breast vascular maps on dynamic contrast-enhanced MRI after primary chemotherapy of locally advanced breast cancer.
Martincich L; Bertotto I; Montemurro F; Ponzone R; Carbonaro LA; Regge D; Sardanelli F
AJR Am J Roentgenol; 2011 May; 196(5):1214-8. PubMed ID: 21512094
[TBL] [Abstract][Full Text] [Related]
38. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy.
Knopp MV; Brix G; Junkermann HJ; Sinn HP
Magn Reson Imaging Clin N Am; 1994 Nov; 2(4):633-58. PubMed ID: 7489314
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity and specificity of unilateral edema on T2w-TSE sequences in MR-Mammography considering 974 histologically verified lesions.
Baltzer PA; Yang F; Dietzel M; Herzog A; Simon A; Vag T; Gajda M; Camara O; Kaiser WA
Breast J; 2010; 16(3):233-9. PubMed ID: 20565468
[TBL] [Abstract][Full Text] [Related]
40. [MR mammography in patients at risk].
Kaiser WA; Mittelmeier O
Rofo; 1992 Jun; 156(6):576-81. PubMed ID: 1617179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
